1 / 82

LYMPHOMA - Non-Hodgkin lymphoma - Hodgkin lymphoma (Hodgkin disease)

LYMPHOMA - Non-Hodgkin lymphoma - Hodgkin lymphoma (Hodgkin disease). Agnieszka Tomaszewska Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, 12 JAN 2006. Lymphoma - definition.

kandyw
Download Presentation

LYMPHOMA - Non-Hodgkin lymphoma - Hodgkin lymphoma (Hodgkin disease)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. LYMPHOMA- Non-Hodgkin lymphoma- Hodgkin lymphoma (Hodgkin disease) Agnieszka Tomaszewska Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, 12 JAN 2006

  2. Lymphoma - definition • Lymphoma (or malignant lymphoma) – a neoplasm of cells derived from lymphocytes or lymphocyte precursors • Lymphoma vs lymphoid leukemia: • Lymphoma – a neoplasm manifesting primarily as a tumor of lymph nodes or related organs (e.g. spleen, liver) • Leukemia – proliferation of abnormal cells (lymphocytes or lymphocytes precursors) in the bone marrow and blood

  3. Normal lymph node architecture • Afferent lymphatic vessel • Sinus • Nodule (follicle): germinal center, mantle zone, marginal zone • Capsule • Medulla • Valve to prevent backflow • Efferent lymphatic vessel

  4. Human lymphatic system

  5. Principles of the classification of lymphoma • There are two main categories: • Non-Hodgkin lymphoma • B-cell lymphomas • T-cell lymphomas • Hodgkin disease (lymphoma)

  6. The World Health Organization Classification of Lymphoid Neoplasms (2001) • B-cell neoplasms • Precursor B-cell neoplasms • Precursor B lymphoblastic leukemia/lymphoma (precursor B-cell acute lymphoblastic leukemia) • Mature (peripheral) B-cellneoplasms with leukemic presentation

  7. The World Health Organization Classification of Lymphoid Neoplasms (2001) (cont.) • Mature (peripheral) B-cell neoplasms with leukemic presentation • Chronic lymphocytic leukemia (CLL)/B-cell small lymphocytic lymphoma (SLL) • B-cell prolymphocytic leukemia • Lymphoplasmacytic lymphoma (Waldenström’s Primary Macroglobulinemia) • Splenic marginal zone B-cell lymphoma (+/- villus lymphocytes) (SMZL)

  8. The World Health Organization Classification of Lymphoid Neoplasms (2001) (cont.) • Mature (peripheral) B-cell neoplasms with leukemic presentation (cont.) • Hairy cell leukemia (HCL) • Plasma cell neoplasms • Extranodal marginal zone B-cell lymphoma of MALT type (MALT lymphoma)

  9. The World Health Organization Classification of Lymphoid Neoplasms (2001) (cont.) • Mature (peripheral) B-cell neoplasms node-based • Nodal marginal zone B-cell lymphoma (MZL) • Follicular lymphoma (FL) • Mantle cell lymphoma (MCL) • Diffuse large B-cell lymphoma (DLBCL) • Burkitt’s lymphoma/leukemia • Lymphomatoid granulomatosis

  10. The World Health Organization Classification of Lymphoid Neoplasms (2001) (cont.) • T-cell and NK-cell neoplasms • Precursor T-cell neoplasms • Precursor T lymphoblastic leukemia/lymphoma (precursor T-cell acute lymphoblastic leukemia) • Mature (peripheral) T-cell neoplasms with leukemic presentation

  11. The World Health Organization Classification of Lymphoid Neoplasms (2001) (cont.) • Mature (peripheral) T-cell neoplasms with leukemic presentation • T-cell prolymphocytic leukemia • T-cell large granular lymphocytic leukemia • Aggressive NK-cell leukemia • Adult T-cell lymphoma/leukemia (HTLV1+)

  12. The World Health Organization Classification of Lymphoid Neoplasms (2001) (cont.) • Mature (peripheral) T-cell neoplasms, various types of presentation • Extranodal NK/T-cel lymphoma, nasal type • Enteropathy-type T-cell lymphoma • Hepatosplenic T-cell lymphoma • Subcutaneous panniculitis-like T-cell lymphoma • Blastic NK-cell lymphoma

  13. The World Health Organization Classification of Lymphoid Neoplasms (2001) (cont.) • Mature (peripheral) T-cell neoplasms, various types of presentation (cont.) • Mycosis fungoides/Sézary syndrome • Primary cutaneous CD30+ T-cell lymphoproliferative disorders • Peripheral T-cell lymphoma, unspecified • Angioimmunoblastic T-cell lymphoma • Primary systemic anaplastic large cell lymphoma

  14. The World Health Organization Classification of Lymphoid Neoplasms (2001) (cont.) • Hodgkin’s lymphoma (Hodgkin’s disease) • Nodular lymphocyte predominant Hodgkin’s lymphoma • Classical Hodgkin’s lymphoma • Nodular sclerosis (most common) • Mixed cellularity • Lymphocyte depleted (extremely rare)

  15. Grouping lymphomas by clinical behaviour • Indolent (slow growing) but usually incurable • CLL/SLL • FL except the large-cell type • Some MZL, gastric MALT lymphoma is often curable in the early stages

  16. Grouping lymphomas by clinical behaviour • Fairly aggressive if untreated, but may becured with appropriate therapy • HD • FL large-cell type • DLBCL

  17. Grouping lymphomas by clinical behaviour • Fairly aggressive and incurable • MCL • Extremely aggressive if untreated, but potentiallycurable with appropriate therapy • Burkitt lymphoma • Lymphoblastic lymphoma

  18. Frequency of lymphoid neoplasms (WHO)

  19. Diagnosis of lymphoma • History • Age of the patient (pediatric/adult) • History of nodes (rapid, slow growth) • Pain • Local or systemic symptoms (unexplained fever, weight loss, night sweats) • Fatigue • Pruritus • Dermatosis, rash • Overall performance status

  20. Diagnosis of lymphoma • Physical examination • Areas of palpable lymphadenopathy (size, location, tenderness) • Size of liver and spleen • Bony tenderness • Neurologic abnormalities

  21. Diagnosis of lymphoma • Laboratory studies • CBC (complete blood count), differential and platelet count, • Erythrocyte sedimentation rate (esp. for HD) • Serum alkaline phosphatase, lactic dehydrogenase, albumin, uric acid • Renal function (creatinine, blood urea nitogen–BUN) tests • Liver function tests

  22. Diagnosis of lymphoma • Radiologic studies • Chest radiograph • Computed tomography scan of the chest, abdomen and pelvis • Bone scan or radiograph if symptoms of bone involvement are present • Gallium or positron emission tomography (PET) scan, especially when other radiologic studies are equivocal

  23. Diagnosis of lymphoma • Biopsies • Diagnostic biopsy of affected lymph node (reviewed by experienced hematopathologist !!!) • Bone marrow biopsy, especially when treatment may be modified • Biopsy of suspicious disseminated extranodal sites (e.g. pulmonary or liver lesions) if clinically indicated

  24. Differential diagnosis of lymphadenopathy • Infections (such as common cold, local acute or chronic infections, infectious mononucleosis, tuberculosis, syphilis, toxoplasmosis, cytomegalovirus, HIV, cat-scratch fever) • Drugs (e.g. phenytoin) • Connective tissue disorders (e.g. systemic lupus erytematosus, dermatomyositis, scleroderma) • Metastatic cancer • Primary lymphoid malignancies (e.g. non-HL, HD)

  25. Distinctions between palpable lymph nodes

  26. Non-Hodgkin lymphomas – selected examples (clinical features, prognostic factors, staging systems, treatment) • CLL • FL • DLBCL • Mycosis fungoides/Sezary Syndrome

  27. Chronic lymphocytic leukemia (B-cell CLL) • Most common leukemia in the Western Hemisphere (40% of all leukemias over the age 65 years) • Median age of presentation is between 65 and 70 years, but 20-30% of patients is under the age of 55 years • 20-30 times commoner in Europe, North American white and black populations than in India, China or Japan • Male/female ratio is appr. 2:1

  28. Chronic lymphocytic leukemia (B-cell CLL)-diagnosis • Lymphocytes > 5 x 109/L; ≥ 1 B-cell marker (CD19, CD20, CD23) + CD5 (without other pan-T cell markers), B-cell is monoclonal (expression of either κ or λ, low density of surface immunoglobulin sIg • Atypical cells (e.g. prolymphocytes) < 55% • Duration of lymphocytosis – none required • Bone marrow lymphocytes ≥ 30%

  29. Chronic lymphocytic leukemia (B-cell CLL) – Rai staging system

  30. B-CLL – Binet staging system

  31. B-CLL prognostic factors

  32. B-CLL prognostic factors (cont.)

  33. B-CLL – indications for treatment • Progressive marrow failure-the development or worsening of anaemia and/or thrombocytopenia • Massive (>10cm) or progressive lymphadenopathy • Massive (>6cm) or progressive splenomegaly • Progressive lymphocytosis: • >50% increase over 2 months • Lymphocyte doubling time (LDT)<6 months • Systemic symptoms • Autoimmune cytopenias (AIHA, ITP)

  34. Management of B-CLL • Patient-related factors (age, PS, co-morbid conditions, patient wishes) • Disease-related factors (the severity of symptoms, adverse prognostic factors) • Treatment-related factors (the degree and duration of response to prior treatments, contra-indications to, side-effects from)

  35. Treatment strategy for B-CLL • Early stage CLL • „watchfull waiting” • „Treatment of early stage with chlorambucil is not indicated” (grade A recomendation, level Ia evidence) • Advanced or progressive disease • Alkylating agents (chlorambucil +/-prednison, COP, CHOP) • Purine analogues (fludarabine, cladribine – alone or in combinations with cyclophosphamide, mitoxantrone) • Monoclonal antibodies (alemtuzumab, rituximab – as a second line treatment) • Transplantation in CLL: autologous transplantation; allogeneic transplantation with low intensity conditioning regimens (RIC-alloTx)

  36. Lymphomatous transformation in CLL • 5-10% of patients with CLL develop more aggressive form of lymphoma - Richter’s transformation of CLL (Richter, 1928) • No standard therapy can be recommended for Richter’s syndrome (CHOP, experimental therapy with monoclonal antibodies, cisplatin/fludarabine based chemotherapy is used)

  37. Diffuse large B-cell lymphoma (DLBCL) • The most frequent type of non-Hodgkin’s lymphoma • An aggressive disease if untreated • Quite responsive to chemotherapy (~ 50% of pts may be cured)

  38. Ann Arbor staging system(for non-Hodgkin’s lymphoma and for Hodgkin’s disease)

  39. Ann Arbor staging system(for non-Hodgkin’s lymphoma and for Hodgkin’s disease) cont.

  40. Ann Arbor staging (cont.) • „B” symptoms: fever, night sweats or unexplained loss of 10% or more body weight in the 6 months preceding diagnosis • „A” – absence of these symptoms • „E” – involvement of an extralymphatic site • „S” – splenic involvement

  41. IPI for DLBCL (and aggressive non-Hodgkin’s lymphomas) • Age (<60 vs ≥60) • Tumor stage (I-II vs III-IV) • The number of extranodal sites (≤1 vs >1) • PS (0-1 vs ≥2) • LDH level (normal vs elevated)

  42. IPI for DLBCL (and aggressive non-Hodgkin’s lymphomas) RISK: • Low: 0-1 risk factors • Low-intermediate: 2 risk factors • High-intermediate: 3 risk factors • High: 4-5 risk factors

  43. IPI for DLBCL (and aggressive non-Hodgkin’s lymphomas)

  44. DLBCL - treatment • Always chemotherapy (CHOP, other regimens) • Chemoimmunotherapy (CHOP+rituximab) • High-dose chemotherapy with autologous-SCT

  45. Follicular lymphoma (FL) • Common in the Western Hemisphere • FL cells closely mimic the cells of the normal germinal center of the lymphoid follicle • Indolent – fewer mitotic figures and less cell turnover than its benign counterpart follicular hyperplasia • Most cases t(14;18), which juxtaposes the bcl-2 gene to Ig Heavy-chain gene

  46. FL – International Prognostic Index (FLIPI) • Age (>60 years vs ≤ 60 years) • Ann Arbor stage (III-IV vs I-II) • Hb level (<12 g/dL vs ≥12 g/dL) • Number of nodal areas (>4 vs ≤4) • Serum LDH level (above normal vs normal or below) • Low risk (0-1 adverse factor, 36% pts) • Intermediate risk (2 factors, 37%) • Poor risk (≥3 factors, 27% pts)

  47. FL - treatment • Chemotherapy (COP, CHOP, others) • Rituximab (monoclonal antibody anti-CD20) alone or in combination with chemotherapy (COP-R, CHOP-R) • SCT for FL (autologous-SCT mostly; allogeneic-SCT mortality 30%) • Radioimmunotherapy (combines the antibody- and complement-dependent cytotoxicity of standard monoclonal antibodies with free radical-mediated apoptosis induced by the radioactive isotope): • 131-Iodine Tositumomab (Bexxar) • 90-Yttrium Ibritumomab Tiuxetan (Zevalin) • New agents (galiximab = anti-CD80, zanolimumab = anti-epitope of CD20, temsirolimus, bortezomib=Velcade)

  48. Cutaneous T-cell Lymphoma (CTCL) • Non-Hodgkin’s lymphoma • Spektrum of disesases composed of malignant clonal helper T lymphocytes of CD4 phenotype • Median pts’ age is 50-55 years • Male to female ratio is 2:1 • Unpredictable course

  49. Cutaneous T-cell Lymphoma (CTCL) • Mycosis fungoides (patches, infiltrated plaques, tumors) • Sezary syndrome (the leukemic variant of CTCL): generalized erythroderma, leukemia and lymphadenopathy; malignant T cells with hyperconvoluted cerebriform nuclei circulate in the blood (Sezary cells)

  50. Cutaneous T-cell Lymphoma (CTCL) - diagnosis • characteristic clinical manifestations • routine histology • immunophenotyping, flow cytometry, T-cell receptor gene rearrangement

More Related